• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-183 和 KIAA0101 在侵袭性和恶性垂体肿瘤中的失调。

Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors.

机构信息

Centre de Recherche en Cancérologie de Lyon, INSERM U1052/CNRS UMR 5286 Centre Léon Bérard , Lyon , France ; Université Lyon 1, Université de Lyon , Lyon , France ; ViroScan3D , Trévoux , France.

Centre de Recherche en Cancérologie de Lyon, INSERM U1052/CNRS UMR 5286 Centre Léon Bérard , Lyon , France ; Université Lyon 1, Université de Lyon , Lyon , France ; ProfileXpert, SFR-Est, CNRS UMR-S3453, INSERM US7 , Lyon , France.

出版信息

Front Med (Lausanne). 2015 Aug 10;2:54. doi: 10.3389/fmed.2015.00054. eCollection 2015.

DOI:10.3389/fmed.2015.00054
PMID:26322309
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4530307/
Abstract

Changes in microRNAs (miRNAs) expression in many types of cancer suggest that they may be involved in crucial steps during tumor progression. Indeed, miRNAs deregulation has been described in pituitary tumorigenesis, but few studies have described their role in pituitary tumor progression toward aggressiveness and malignancy. To assess the role of miRNAs within the hierarchical cascade of events in prolactin (PRL) tumors during progression, we used an integrative genomic approach to associate clinical-pathological features, global miRNA expression, and transcriptomic profiles of the same human tumors. We describe the specific down-regulation of one principal miRNA, miR-183, in the 8 aggressive (A, grade 2b) compared to the 18 non-aggressive (NA, grades 1a, 2a) PRL tumors. We demonstrate that it acts as an anti-proliferative gene by directly targeting KIAA0101, which is involved in cell cycle activation and inhibition of p53-p21-mediated cell cycle arrest. Moreover, we show that miR-183 and KIAA0101 expression significantly correlate with the main markers of pituitary tumors aggressiveness, Ki-67 and p53. These results confirm the activation of proliferation in aggressive and malignant PRL tumors compared to non-aggressive ones. Importantly, these data also demonstrate the ability of such an integrative genomic strategy, applied in the same human tumors, to identify the molecular mechanisms responsible for tumoral progression even from a small cohort of patients.

摘要

许多类型癌症中 microRNAs(miRNAs)表达的变化表明它们可能参与肿瘤进展的关键步骤。事实上,已经描述了垂体肿瘤发生中 miRNAs 的失调,但很少有研究描述它们在垂体肿瘤向侵袭性和恶性进展过程中的作用。为了评估 miRNAs 在催乳素(PRL)肿瘤进展过程中分层事件级联中的作用,我们使用整合基因组方法将临床病理特征、全局 miRNA 表达和相同人类肿瘤的转录组谱联系起来。我们描述了在 8 个侵袭性(A,2b 级)与 18 个非侵袭性(NA,1a、2a 级)PRL 肿瘤相比,一个主要 miRNA,miR-183 的特异性下调。我们证明它通过直接靶向 KIAA0101 作为一种抗增殖基因,KIAA0101 参与细胞周期激活和抑制 p53-p21 介导的细胞周期阻滞。此外,我们表明 miR-183 和 KIAA0101 的表达与垂体肿瘤侵袭性的主要标志物 Ki-67 和 p53 显著相关。这些结果证实了与非侵袭性肿瘤相比,侵袭性和恶性 PRL 肿瘤中增殖的激活。重要的是,这些数据还证明了这种整合基因组策略在相同人类肿瘤中的应用能够识别肿瘤进展的分子机制,即使在患者数量较少的情况下也是如此。

相似文献

1
Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors.miR-183 和 KIAA0101 在侵袭性和恶性垂体肿瘤中的失调。
Front Med (Lausanne). 2015 Aug 10;2:54. doi: 10.3389/fmed.2015.00054. eCollection 2015.
2
Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors.综合基因组分析确定 11p 染色体缺失对侵袭性垂体催乳素瘤转录组活性的影响。
Brain Pathol. 2011 Sep;21(5):533-43. doi: 10.1111/j.1750-3639.2011.00476.x. Epub 2011 Feb 23.
3
A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.用于催乳素垂体瘤侵袭、增殖和侵袭性的诊断标志物集。
Endocr Relat Cancer. 2007 Sep;14(3):887-900. doi: 10.1677/ERC-07-0062.
4
miR-429 inhibits metastasis by targeting KIAA0101 in Soft Tissue Sarcoma.微小RNA-429通过靶向KIAA0101抑制软组织肉瘤转移。
Exp Cell Res. 2017 Aug 1;357(1):33-39. doi: 10.1016/j.yexcr.2017.04.017. Epub 2017 Apr 19.
5
The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop.靶向PTTG1的微小RNA miR-329、miR-300、miR-381和miR-655可抑制垂体肿瘤细胞的肿瘤发生,并参与p53/PTTG1调节反馈回路。
Oncotarget. 2015 Oct 6;6(30):29413-27. doi: 10.18632/oncotarget.5003.
6
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations.肝细胞肿瘤中的微小RNA谱与临床特征及癌基因/肿瘤抑制基因突变相关。
Hepatology. 2008 Jun;47(6):1955-63. doi: 10.1002/hep.22256.
7
Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma.侵袭性甲状腺乳头状癌中 microRNA 和 mRNA 表达谱的综合分析。
Mol Med Rep. 2013 Nov;8(5):1353-8. doi: 10.3892/mmr.2013.1699. Epub 2013 Sep 24.
8
Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors.癌症相关 miRNAs 的失调是良性和恶性人类乳腺肿瘤中的常见事件。
Carcinogenesis. 2014 Jan;35(1):76-85. doi: 10.1093/carcin/bgt333. Epub 2013 Oct 8.
9
Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.深度测序揭示三阴性乳腺癌中失调的微小RNA
Mol Cancer. 2015 Feb 10;14:36. doi: 10.1186/s12943-015-0301-9.
10
Differentially Expressed miRNAs Influence Metabolic Processes in Pituitary Oncocytoma.差异表达的 miRNA 影响垂体嗜酸性细胞瘤中的代谢过程。
Neurochem Res. 2019 Oct;44(10):2360-2371. doi: 10.1007/s11064-019-02789-2. Epub 2019 Apr 3.

引用本文的文献

1
The clinical effects of miR-26a, miR-16, let-7, miR-128a and miR-223 in acromegaly.miR-26a、miR-16、let-7、miR-128a和miR-223在肢端肥大症中的临床作用。
Ir J Med Sci. 2025 Aug 11. doi: 10.1007/s11845-025-04068-2.
2
A Brief Overview of Molecular Biology in Pituitary Adenomas with a Focus on Aggressive Lesions.垂体腺瘤分子生物学概述:聚焦侵袭性病变
Int J Mol Sci. 2025 Apr 15;26(8):3717. doi: 10.3390/ijms26083717.
3
Elucidating Clinical Queries for Tailored Therapy in Patients with Prolactinoma.阐明泌乳素瘤患者个体化治疗的临床问题。

本文引用的文献

1
Mir-23b and miR-130b expression is downregulated in pituitary adenomas.垂体腺瘤中Mir-23b和miR-130b的表达下调。
Mol Cell Endocrinol. 2014 Jun 5;390(1-2):1-7. doi: 10.1016/j.mce.2014.03.002. Epub 2014 Mar 28.
2
MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.MYCN 和 HDAC2 合作抑制神经母细胞瘤中的 miR-183 信号。
Nucleic Acids Res. 2013 Jul;41(12):6018-33. doi: 10.1093/nar/gkt346. Epub 2013 Apr 26.
3
p15(PAF) is an Rb/E2F-regulated S-phase protein essential for DNA synthesis and cell cycle progression.
Endocrinol Metab (Seoul). 2024 Dec;39(6):819-826. doi: 10.3803/EnM.2024.2057. Epub 2024 Oct 14.
4
Study on the Mechanism of Competing Endogenous Network of ' D.Don- in the Treatment of NSCLC based on Bioinformatics, Molecular Dynamics and Experimental Verification.基于生物信息学、分子动力学和实验验证的“冬凌草治疗非小细胞肺癌竞争性内源网络机制研究”
Curr Comput Aided Drug Des. 2025;21(3):403-423. doi: 10.2174/0115734099288771240419110716.
5
The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations.生长激素和泌乳素分泌型垂体瘤的 ER∝ 表达的预后价值:临床病理相关性。
Int J Mol Sci. 2023 Nov 10;24(22):16162. doi: 10.3390/ijms242216162.
6
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.侵袭性 PitNETs 及潜在的靶向治疗:分子和遗传途径的系统综述。
Int J Mol Sci. 2023 Oct 29;24(21):15719. doi: 10.3390/ijms242115719.
7
Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.帕唑帕尼的治疗反应:泌乳素瘤侵袭性的分子异常的病例报告及文献复习。
Front Endocrinol (Lausanne). 2023 Jul 17;14:1195792. doi: 10.3389/fendo.2023.1195792. eCollection 2023.
8
Major Genetic Motifs in Pituitary Adenomas: A Practical Literature Update.垂体腺瘤的主要遗传特征:实用文献更新。
World Neurosurg. 2023 Jan;169:43-50. doi: 10.1016/j.wneu.2022.09.036. Epub 2022 Sep 14.
9
Proliferating cell nuclear antigen clamp associated factor, a potential proto-oncogene with increased expression in malignant gastrointestinal tumors.增殖细胞核抗原钳相关因子,一种在恶性胃肠道肿瘤中表达增加的潜在原癌基因。
World J Gastrointest Oncol. 2021 Oct 15;13(10):1425-1439. doi: 10.4251/wjgo.v13.i10.1425.
10
MiRNAs as Noninvasive Biomarkers and Therapeutic Agents of Pituitary Adenomas.微小 RNA 作为垂体腺瘤的非侵入性生物标志物和治疗剂。
Int J Mol Sci. 2020 Oct 2;21(19):7287. doi: 10.3390/ijms21197287.
p15(PAF) 是一种 Rb/E2F 调节的 S 期蛋白,对 DNA 合成和细胞周期进程至关重要。
PLoS One. 2013 Apr 4;8(4):e61196. doi: 10.1371/journal.pone.0061196. Print 2013.
4
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.一种新的垂体腺瘤预后临床病理分类:410 例患者 8 年术后随访的多中心病例对照研究。
Acta Neuropathol. 2013 Jul;126(1):123-35. doi: 10.1007/s00401-013-1084-y. Epub 2013 Feb 12.
5
TGF-β signaling and epithelial-mesenchymal transition in cancer progression.TGF-β 信号通路与癌症进展中的上皮间质转化。
Curr Opin Oncol. 2013 Jan;25(1):76-84. doi: 10.1097/CCO.0b013e32835b6371.
6
Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management.侵袭性和恶性泌乳素垂体瘤:病理诊断和患者管理。
Pituitary. 2013 Dec;16(4):515-22. doi: 10.1007/s11102-012-0448-y.
7
miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells.miR-183 通过下调 F5M2 细胞中 Ezrin 的表达抑制骨肉瘤的转移。
Int J Mol Med. 2012 Nov;30(5):1013-20. doi: 10.3892/ijmm.2012.1111. Epub 2012 Aug 24.
8
MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro.微小 RNA miR-107 在垂体腺瘤中过度表达,并在体外抑制芳香烃受体相互作用蛋白的表达。
Am J Physiol Endocrinol Metab. 2012 Sep 15;303(6):E708-19. doi: 10.1152/ajpendo.00546.2011. Epub 2012 Jul 17.
9
Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway.功能筛选分析显示,miR-26b 和 miR-128 通过激活 PTEN-AKT 通路成为垂体生长激素腺瘤生长的核心调控因子。
Oncogene. 2013 Mar 28;32(13):1651-9. doi: 10.1038/onc.2012.190. Epub 2012 May 21.
10
Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation.KIAA0101 的变体 1 在肝癌中过表达,通过抑制 p53 激活来防止阿霉素诱导的细胞凋亡。
Hepatology. 2012 Nov;56(5):1760-9. doi: 10.1002/hep.25834. Epub 2012 Oct 14.